171 related articles for article (PubMed ID: 10187653)
21. Spending on pharmaceuticals in Italy: macro constraints with local autonomy.
Mapelli V; Lucioni C
Value Health; 2003; 6 Suppl 1():S31-45. PubMed ID: 12846924
[TBL] [Abstract][Full Text] [Related]
22. [International reference prices and cost minimization analysis for the regulation of medicine prices in Colombia].
Vacca C; Acosta A; Rodriguez I
Value Health; 2011; 14(5 Suppl 1):S16-9. PubMed ID: 21839891
[TBL] [Abstract][Full Text] [Related]
23. In practice: the NHS market in the United Kingdom. Health Policy Network of the National Health Service Consultant's Association and the National Health Service Support Federation.
J Public Health Policy; 1995; 16(4):452-91. PubMed ID: 8907766
[TBL] [Abstract][Full Text] [Related]
24. Costs of paying higher prices for equivalent effects on the Pharmaceutical Benefits Scheme.
Karnon J; Edney L; Sorich M
Aust Health Rev; 2017 Mar; 41(1):1-6. PubMed ID: 26954612
[TBL] [Abstract][Full Text] [Related]
25. [Risk sharing methods in middle income countries].
Inotai A; Kaló Z
Acta Pharm Hung; 2012; 82(1):43-52. PubMed ID: 22570986
[TBL] [Abstract][Full Text] [Related]
26. Switch from public to private retail pharmaceutical expenditures: evidence from a time series analysis in Italy.
Lenzi J; Gianino MM
BMJ Open; 2022 Mar; 12(3):e055421. PubMed ID: 35260457
[TBL] [Abstract][Full Text] [Related]
27. Cost containment and health care reform: a study of the European Union.
Abel-Smith B; Mossialos E
Health Policy; 1994 May; 28(2):89-132. PubMed ID: 10171936
[TBL] [Abstract][Full Text] [Related]
28. Potential impact of policy regulation and generic competition on sales of cholesterol lowering medication, antidepressants and acid blocking agents in Belgium.
Fraeyman J; Van Hal G; De Loof H; Remmen R; De Meyer GR; Beutels P
Acta Clin Belg; 2012; 67(3):160-71. PubMed ID: 22897063
[TBL] [Abstract][Full Text] [Related]
29. Impact of Health Policy Changes on Trends in the Pharmaceutical Market in Turkey.
Yılmaz ES; Koçkaya G; Yenilmez FB; Saylan M; Tatar M; Akbulat A; Gürsöz H; Kerman S
Value Health Reg Issues; 2016 Sep; 10():48-52. PubMed ID: 27881277
[TBL] [Abstract][Full Text] [Related]
30. Drug Policy in Bulgaria.
Dimova A; Rohova M; Atanasova E; Kawalec P; Czok K
Value Health Reg Issues; 2017 Sep; 13():50-54. PubMed ID: 29073988
[TBL] [Abstract][Full Text] [Related]
31. Issues in drug pricing, reimbursement, and access in China with references to other Asia-Pacific region.
Chen Y; Schweitzer SO
Value Health; 2008 Mar; 11 Suppl 1():S124-9. PubMed ID: 18387056
[TBL] [Abstract][Full Text] [Related]
32. Financial Outcomes of Managed Entry Agreements for Pharmaceuticals in Italy.
Trotta F; Guerrizio MA; Di Filippo A; Cangini A
JAMA Health Forum; 2023 Dec; 4(12):e234611. PubMed ID: 38153808
[TBL] [Abstract][Full Text] [Related]
33. Lessons from international experience in controlling pharmaceutical expenditure. I: Influencing patients.
Freemantle N; Bloor K
BMJ; 1996 Jun; 312(7044):1469-71. PubMed ID: 8664631
[TBL] [Abstract][Full Text] [Related]
34. Managing prices for hospital pharmaceuticals: a successful strategy for New Zealand?
Tordoff JM; Norris PT; Reith DM
Value Health; 2005; 8(3):201-8. PubMed ID: 15877592
[TBL] [Abstract][Full Text] [Related]
35. The effects of new pricing and copayment schemes for pharmaceuticals in South Korea.
Lee IH; Bloor K; Hewitt C; Maynard A
Health Policy; 2012 Jan; 104(1):40-9. PubMed ID: 22000599
[TBL] [Abstract][Full Text] [Related]
36. Future European health care: cost containment, health care reform and scientific progress in drug research.
Emilien G
Int J Health Plann Manage; 1997; 12(2):81-101. PubMed ID: 10173136
[TBL] [Abstract][Full Text] [Related]
37. How to solve financing gap to ensure patient access to patented pharmaceuticals in CEE countries? - the good, the bad, and the ugly ways.
Inotai A; Kaló Z
Expert Rev Pharmacoecon Outcomes Res; 2019 Dec; 19(6):627-632. PubMed ID: 31810392
[No Abstract] [Full Text] [Related]
38. Spending on medicines in Israel in an international context.
Sax P
Isr Med Assoc J; 2005 May; 7(5):286-91. PubMed ID: 15909459
[TBL] [Abstract][Full Text] [Related]
39. Implication of external price referencing and parallel trade on pharmaceutical expenditure: indirect evidence from lower-income European countries.
Elek P; Takács E; Merész G; Kaló Z
Health Policy Plan; 2017 Apr; 32(3):349-358. PubMed ID: 27697777
[TBL] [Abstract][Full Text] [Related]
40. More of the same is not enough.
Willison DJ
Healthc Pap; 2002; 3(1):47-55; discussion 87-94. PubMed ID: 12811111
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
